A clinical-stage biopharmaceutical firm developing proprietary antibody-drug conjugates for oncology and rare diseases with a focus on transforming late-stage assets into approved therapies.
TXMD offers exposure to a promising ADC platform that could yield blockbuster assets if clinical trials succeed, particularly in the high-value pediatric oncology space. The company's strong cash position relative to its current burn rate provides sufficient runway to advance key candidates toward late-stage development without immediate dilution. A successful readout from any major trial could trigger significant multiple expansion given the scarcity of approved therapies in its target indications.
The drastic drop in revenue over the last two years and persistent net losses highlight severe financial fragility, with a retained earnings deficit exceeding $950M suggesting historical burn issues. Investors face substantial dilution risk as the company likely needs frequent capital raises to sustain operations before achieving commercialization. The lack of approved products means the stock price is entirely speculative, relying on binary clinical outcomes that carry a high probability of failure.
TherapeuticsMD, Inc. (TXMD) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs in oncology and rare diseases. The company operates primarily in the United States with a pipeline targeting solid tumors and pediatric cancers, leveraging its proprietary antibody-drug conjugate (ADC) platform to advance multiple candidates through clinical development. With recent revenue of $1.8M in 2024 and a market cap driven by significant other shareholders equity, TXMD seeks to transform early-stage science into approved medicines.
TherapeuticsMD reported revenue of $1.8M in 2024, a slight increase from the prior year but down significantly from 2022 levels, reflecting a typical transition period for clinical-stage biotech firms focusing on R&D rather than sales. The company incurred a net loss of $2.2M, consistent with its investment phase, while maintaining positive operating cash flow of $732k and ending the year with $5.1M in cash and equivalents. General and administrative expenses totaled $4.7M, driven largely by personnel costs associated with advancing the oncology pipeline.
The global biopharmaceutical industry is experiencing a surge in antibody-drug conjugate (ADC) development, with major investors prioritizing oncology and rare disease targets. Companies in this space face intense competition from established giants and smaller biotechs, requiring robust pipeline depth and efficient clinical execution to survive. Regulatory pathways for orphan drugs are increasingly favorable, offering potential incentives but also raising the bar for proof of efficacy.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $70.0M | $1.3M | $1.8M |
| Cost of Revenue | $1.4M | $0 | $0 |
| Gross Profit | $68.6M | $1.3M | $1.8M |
| Operating Expenses | $67.4M | $9.8M | $6.5M |
| Operating Income | $1.2M | $-8.5M | $-4.8M |
| G&A | $57.9M | $8.9M | $4.7M |
| Stock-Based Comp | $11.6M | $1.3M | $264.0K |
| D&A | $1.2M | $922.0K | $509.0K |
| Depreciation | $600.0K | $100.0K | — |
| Amortization | — | $500.0K | — |
| Other OpEx | $9.5M | $922.0K | $1.8M |
| Non-Operating Income | $-117.0K | $781.0K | $2.4M |
| Interest Expense | $36.1M | $300.0K | — |
| Interest Income | — | — | $144.9K |
| Pre-Tax Income | $1.1M | $-7.7M | $-2.3M |
| Income Tax | $0 | $-43.0K | $-31.0K |
| Continuing Ops | $1.1M | $-7.7M | $-2.3M |
| Discontinued Ops | $110.9M | $-2.6M | $131.0K |
| Net Income | $112.0M | $-10.3M | $-2.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $112.0M | $-10.3M | $-2.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $55.4M | $11.8M | $12.3M |
| Cash & Equivalents | — | — | $5.1M |
| Prepaid Expenses | $6.0M | $4.0M | $3.6M |
| Other Current Assets | $49.3M | $7.8M | $3.6M |
| Long-Term Assets | $35.1M | $31.5M | $26.6M |
| PP&E (Net) | $78.0K | — | — |
| Intangibles | $6.9M | $6.1M | $4.3M |
| Operating Leases | $7.6M | $6.9M | $6.1M |
| Other LT Assets | $20.5M | $18.5M | $16.1M |
| Total Assets | $90.5M | $43.3M | $38.8M |
| Current Liabilities | $46.8M | $6.9M | $5.2M |
| Accounts Payable | $2.2M | $27.0K | $258.0K |
| Current Leases | $1.4M | $1.5M | $1.6M |
| Other Current Liab | $43.3M | $5.4M | $3.3M |
| Long-Term Liabilities | $8.5M | $7.2M | $6.3M |
| LT Operating Leases | $7.4M | $6.5M | $5.5M |
| Other LT Liab | $1.1M | $636.0K | $744.0K |
| Total Liabilities | $55.3M | $14.0M | $11.5M |
| Shareholders' Equity | $35.1M | $29.3M | $27.4M |
| Paid-In Capital | — | $978.9M | — |
| Retained Earnings | $-939.4M | $-949.6M | $-951.8M |
| Total L&E | $90.5M | $43.3M | $38.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $112.0M | $-10.3M | $-2.2M |
| Non-Cash Adjustments | $-126.0M | $-18.7M | $5.9M |
| Working Capital Changes | $9.9M | $-19.2M | $-3.0M |
| Cash from Operations | $-4.1M | $-48.1M | $732.0K |
| Cash from Investing | $223.5M | $0 | — |
| Cash from Financing | $-235.2M | $3.2M | — |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-15.8M | $-45.0M | $732.0K |
| Beginning Cash | $79.0M | $49.3M | $4.3M |
| Ending Cash | $64.9M | $4.3M | $5.1M |
Oncology Pipeline: Development of novel antibody-drug conjugates (ADCs) targeting solid tumors, which represented the majority of recent revenue activity. Rare Disease Programs: Early-stage candidates addressing unmet needs in pediatric and adult rare disease populations. Licensing and Collaboration: Revenue derived from strategic partnerships and licensing agreements to advance specific asset classes externally.
Cash Burn and Liquidity Constraints: The company reported a net loss of $2.2M in 2024 with limited cash reserves relative to operating expenses, raising concerns about runway extension without additional financing. Revenue Volatility: Experienced a dramatic decline from $70M in 2022 to $1.8M in 2024, indicating potential instability in current revenue streams or recognition models. Clinical Development Uncertainty: As a clinical-stage company with no approved products yet, the risk of trial failure is high and could lead to total loss of invested capital. Regulatory Hurdles: Dependence on FDA approval for complex ADC molecules introduces significant timeline and cost uncertainties that could impact stock valuation.
Proprietary ADC Platform: Utilizes a unique chemical linker technology designed to improve drug delivery and reduce systemic toxicity compared to standard-of-care therapies. Strategic Pipeline Assets: Holds rights to multiple late-stage or mid-stage candidates with potential for significant value upon regulatory approval. Niche Market Focus: Concentrates resources on high-value, orphan-designated indications that often lack effective current treatments.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.